Pharmidex is excited to support the 2025 Horizon Europe Marie Skłodowska-Curie Actions (MSCA) Staff Exchanges hybrid information session.
June 3, 2025
This initiative provides a fantastic opportunity to learn directly from key voices across the MSCA community, including insights from a project coordinator, beneficiary, and third-country partner, all sharing valuable lessons and best practices.
We are proud to announce that our Managing Director,
Professor
Mo Alavijeh (Pharmidex,
University of Hertfordshire), will participate in the Round Table Discussion on “MSCA Staff Exchanges: Challenges and Opportunities”, including an interactive Q&A session.
Mo will be attending in person at the
Universitat d'Alacant and is looking forward to engaging with attendees, building new connections, and exploring collaborative opportunities, particularly with those interested in working alongside a UK-based SME deeply committed to international research excellence.
Monika Holik,
Begoña Arano,
Sotirios Kiokias,
Rodrigo Gutierrez Dominguez,
Xavier Eekhout Chicharro,
Joaquin Silvestre,
Izaskun Lacunza,
Julio Marchamalo Amado,
Mónika Holik
We’re pleased to share that Pharmidex has been selected as a partner in the EIC - European Innovation Council Ecosystem Partnership Programme. Our services are now featured on the EIC Service Catalogue, making them accessible to innovative companies and projects supported by the EIC across Europe. This is a great opportunity to further support cutting-edge biotech and life sciences programmes by providing: 🔬 Preclinical in vivo pharmacology 🧪 Bioanalysis (LC–MS/MS, qPCR, ELISA) 📊 Translational and mechanistic studies 🧫 Histology and pathology We look forward to working with EIC beneficiaries and contributing to the development of the next generation of therapies. If you are part of the EIC ecosystem and looking for a flexible, science-led CRO partner, we would be delighted to connect.
We are delighted to congratulate EpiEndo Pharmaceuticals and the Institute of Pharmaceutical Science, King's College London on the publication of two exciting studies exploring the therapeutic potential of EP395: 📄 “ The Effect of the Novel Macrolide Glasmacinal (EP395) on Allergen-Induced Eosinophil Infiltration into the Lung” published in "Lung" 📄 “Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation” published in "Pulmonary Pharmacology & Therapeutics" These studies provide valuable insights into the role of EP395 in modulating inflammatory responses in respiratory disease, supporting its potential as a novel therapeutic approach. At Pharmidex , we are proud to have contributed to this work through our Respiratory Department, supporting the in vivo studies and helping advance these important findings. We look forward to continuing our collaboration and supporting innovative programmes in respiratory drug discovery and development.
We are pleased to share our latest publication: “Magnetic field-induced drug delivery from magnetic microporous nanocomposites through magnetic nanoparticles heating or motion” , published in the journal Materials & Design . This work explores innovative approaches to magnetically triggered drug delivery, leveraging the unique properties of magnetic nanoparticles to enable controlled release through heating and motion mechanisms. These advances have the potential to open new avenues in targeted therapies and precision medicine. We would like to sincerely thank our collaborators for their valuable contributions to this research: -CRCT Université de Toulouse Inserm U1037 CNR -Laboratoire de Physique et Chimie des Nano-Objets (LPCNO) CNRS-UPS-INSA -Centro Singular de Investigación en Química Biológica y Materiales Moleculares (CIQUS) We are proud to contribute to cutting-edge research at the interface of nanotechnology and drug delivery and we look forward to continuing collaborations that drive innovation in drug discovery and development. 🔗 Read the full article: https://www.sciencedirect.com/science/article/pii/S0264127526003084?via%3Dihub
